Executive Summary
Across 29 filings on US executive and director changes from April 2026, the dominant theme is leadership transitions with 14 appointments/promotions (48%), 11 resignations/departures (38%), 3 compensation enhancements, and 1 CEO return from medical leave, signaling a mix of proactive team-building in biotech/energy and reactive stability measures amid M&A. Positive sentiment prevails in 8 filings (28%), particularly biotechs (Structure Therapeutics, Prelude, Tango) hiring for Phase 3/clinical catalysts and media (Cineverse, Regis) for growth strategies, while 17 neutrals (59%) reflect routine no-disagreement exits; no explicit YoY revenue/margin declines but comp increases (e.g., Hallador CEO +18.5% YoY base) indicate retention amid $68M EBITDA targets. Portfolio-level patterns show healthcare/biotech outliers with experienced hires boosting pipelines (e.g., 30+ years oncology exp at Prelude), contrasting finance/industrials' interim roles (Corebridge, Kenvue pre-merger). Critical implications include M&A risks (Corebridge $385B AUM merger), board contractions (DuPont 11→10, American Vanguard 9→7 per debt terms), and 2026 catalysts like clinical data (Tango vopimetostat). No broad insider trading patterns but shareholder designees (Hagerty, Ribbon) suggest alignment; capital allocation leans retention via RSUs/sev (Lionsgate 4.5M options, Hallador $2.4M CIC). Actionable: Favor biotech hires for alpha, monitor interims for volatility.
Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from April 08, 2026.
Investment Signals(12)
- HALLADOR ENERGY CO↓(BULLISH)▲
CEO base +18.5% YoY to $800K, CFO +5% to $525K, $68M Adj EBITDA target 2026, $1.2M RSU grants vesting 2027-2029
- Structure Therapeutics Inc.↓(BULLISH)▲
COO Matthew Lang appt (15+ yrs exp Gilead/Myovant), bolstering obesity pipeline to Phase 3 amid competitive field
- REGIS CORP↓(BULLISH)▲
Independent director Bill Charters appt Apr 24 from largest shareholder, CFA exp in restructurings/franchise to execute transformation
- Prelude Therapeutics Inc.↓(BULLISH)▲
CMO Dr. Charles Morris appt Apr 20 (30+ yrs oncology, approvals ONSERDU/ELAHERE), lead MPN/breast cancer programs to clinic 2026
- Lionsgate Studios Corp.↓(BULLISH)▲
CEO Feltheimer contract to 2031, 4.5M options/$11.07 strike + 667K perf RSUs ($17.50-$22.50 goals in 5 yrs), $10M annual equity FY26-29
- SAGA COMMUNICATIONS INC↓(BULLISH)▲
CEO Forgy resumes full duties post-heart surgery leave (Feb13 start), led Q4'25 call Mar12, continuity via COO/CFO
- 374Water Inc.↓(BULLISH)▲
Director Richard Davis appt Apr10 (ex-CEO predecessor, investment banker), coordinates >$120K financings
- Cineverse Corp.↓(BULLISH)▲
CFO Sean McCabe return Apr20 (ad-tech exp Freestar/Jukin), supports IndiCue/Giant acquisitions for balance sheet/strategic growth
- Ribbon Communications Inc.↓(BULLISH)▲
Director Louis Silver appt Apr15 (25+ yrs tech invest, Ceva board), Swarth designee boosts governance
- Tango Therapeutics, Inc.↓(BULLISH)▲
Triple hires (CFO Gall Apr15, CDOO Chua Jun1, SVP Kapty Apr15 ex-iTeos/Novartis), accelerate vopimetostat Phase3/pancreatic data 2026
- EQT Corp↓(BULLISH)▲
All 10 directors elected 88-97% support Apr14 AGM, LTIP shares +34M approved, say-on-pay 485M For
EVP/COO Jordan Mangum appt Apr13 (BCPA credit team), under staffing agreement despite conflicts [NEUTRAL/BULLISH OPERATIONAL]
Risk Flags(10)
- WORLD ACCEPTANCE CORP/CEO Resignation↓[HIGH RISK]▼
R. Chad Prashad resigns Apr13 'other opportunities', interim Janet Matricciani, search ongoing no financial impact disclosed
- TRANS LUX Corp/CEO Transition↓[MEDIUM RISK]▼
Interim CEO Hammock resigns Apr13 no disagreements, new CEO Yantao Yu (Unilumin CFO/stockholder) $26K/yr dual comp
- LENSAR, Inc./CFO Departure↓[HIGH RISK]▼
Thomas Staab resigns May8 'other opportunities' no disagreements, search started, transition as principal officer
- Corebridge Financial, Inc./CFO Change↓[HIGH RISK]▼
CFO Elias Habayeb departs Apr24 pre-Equitable merger, interim CAO Filiaggi until close ($385B AUM risks: reg/integration)
- Kenvue Inc./CFO Stepdown↓[HIGH RISK]▼
Amit Banati steps down May12 pre-Kimberly-Clark merger, interim CAO Howlett +$125K/mo stipend FY26 comp unchanged
- MSC INDUSTRIAL DIRECT CO INC/GC Resignation↓[MEDIUM RISK]▼
SVP/GC Neal Dongre voluntary resign Apr10 no disagreements, stays thru FY26 successor
- STARZ ENTERTAINMENT CORP/GC Retirement↓[MEDIUM RISK]▼
Audrey Lee retires May1, $1.2M+ sev lump sum + equity accel, ineligible 2026 grants
- AMERICAN VANGUARD CORP/Board Shrink↓[MEDIUM RISK]▼
3 directors (Baskin/Gunter/Tiu) not re-elect Apr10 per Mar13 debt terms, board 9→7 +1 lender appt
- DuPont de Nemours, Inc./Director Loss↓[LOW-MEDIUM RISK]▼
Luke Kissam resigns Apr14 to Corteva CEO, board 11→10 no disagreements
- USBC, Inc./Exec Departure↓[MEDIUM RISK]▼
Dir/Pres Erickson out Mar27 post-divestiture, 1-yr $375K sev +167.5K RSU accel
Opportunities(10)
- Structure Therapeutics/Obesity Pipeline↓(OPPORTUNITY)◆
COO hire accelerates aleniglipron Phase3, GPCR platform edge vs competitors
- Prelude Therapeutics/Oncology Catalysts↓(OPPORTUNITY)◆
CMO exp (ImmunoGen/Radius) drives 2026 clinic entry MPN/ER+ breast, multi-approval track record
- Lionsgate Studios/CEO Retention↓(OPPORTUNITY)◆
Extended term + perf equity (stock goals $17.50+ in 5yrs) signals conviction in content growth
- Cineverse Corp/Ad-Tech Synergies↓(OPPORTUNITY)◆
Returning CFO McCabe leverages IndiCue/Giant rev/profit boost post-acquisitions
- Tango Therapeutics/Vopimetostat Data↓(OPPORTUNITY)◆
New C-suite (ex-Novartis/iTeos) targets 2026 pancreatic combo data w/RevMed RAS(ON)
- Hallador Energy/Exec Retention↓(OPPORTUNITY)◆
+18.5% CEO pay + $68M EBITDA target + RSUs/CIC sev enhances alignment for coal/power ops
- Regis Corp/Transformation↓(OPPORTUNITY)◆
Shareholder director (Botti Brown exp) aids franchise restructuring/shareholder value
- EQT Corp/Shareholder Alignment↓(OPPORTUNITY)◆
97% director support + LTIP expansion signals strong governance for nat gas ops
- 374Water Inc/Financing↓(OPPORTUNITY)◆
Ex-CEO director coordinates >$120K deals, wastewater tech growth potential
- Saga Communications/Leadership Stability↓(OPPORTUNITY)◆
CEO full return post-leave, Q4'25 call success under COO/CFO backup
Sector Themes(6)
- Biotech Leadership Ramp-Up(BULLISH PIPELINE)◆
4/29 filings (Structure, Prelude, Tango, incidental) positive CMO/COO/CFO hires w/20-30yrs exp for 2026 Phase3/clinical data (vopimetostat/aleniglipron), avg materiality 7/10; implies pipeline acceleration alpha vs flat sector
- M&A-Driven Interim Shifts(CAUTIONARY)◆
2/29 (Corebridge $385B AUM, Kenvue) CFO changes pre-merger w/interims (Filiaggi/Howlett +stipends), risks reg/integration; 6% of stream but high materiality 8/10, watch synergies
- Compensation Retention Focus(BULLISH CONFIDENCE)◆
4/29 (Hallador +18.5% CEO YoY/$68M EBITDA tgt, Lionsgate 4.5M opts/$10M ann equity, Valmont $525K base/160% stock, NextDecade 130% bonus/36mo CIC sev); avg +10-20% hikes signal talent wars
- Board Contractions/No-Disagreement Exits(NEUTRAL STABILITY)◆
7/29 neutral resignations (DuPont/OGE/AMV etc.) reduce sizes 11→10/9→7 per debt/terms, 100% 'no disagreements'; routine refresh but monitor lender influence
- Media/Entertainment Continuity(BULLISH TURNAROUND)◆
4/29 (Lionsgate extend, Saga return, Starz sev, Cineverse CFO return) emphasize retention post-acq/leave, ad-tech synergies; positive amid content shifts
- Energy/Utilities Director Moves(MIXED)◆
3/29 (Hallador comp up, OGE/EQT AGM strong 88-97% votes); comp hikes/EBITDA tgts vs board exits signal operational focus
Watch List(8)
Interim Matricciani, monitor permanent hire impact on small loan ops post-Prashad exit [Ongoing Apr2026]
Staab exit May8, successor search; track Q2 financials/reporting stability [May8 2026]
Interim Filiaggi to Equitable close, reg approvals/integration risks $385B AUM [Merger Close 2026]
Howlett from May12 to KC merger, FY26 comp/earnings guidance [May12 2026]
Kissam resign May14, proxy amendments; board size to 8 [May14 2026]
Niggli out May29 AGM, founding chair exit [May29 2026]
Vopimetostat pancreatic/combo data presentations [2026 H1/H2]
Perf bonuses/RSUs tied safety/EBITDA thru Dec31 2026, pay Mar2027 [Mar2027]
Filing Analyses(29)
15-04-2026
On April 9, 2026, Hallador Energy Company's Board approved the 2026 Executive Officer Plan, replacing the expired 2024 plan, with base salary increases for named executives: Brent Bilsland (CEO) to $800,000 (+18.5% from $675,000), Todd Telesz (CFO) to $525,000 (+5% from $500,000), and Heath Lovell (COO) to $500,000 (+11.1% from $450,000). The plan includes target performance bonuses of $500,000, $200,000, and $300,000 respectively, tied to safety, Adjusted EBITDA ($68.0M target), discretionary, and strategic goals, plus one-time RSU grants valued at approximately $1,200,000, $275,000, and $400,000. New severance and change-in-control retention provisions were also established, including lump sum payments up to $2,400,000 for Bilsland.
- ·RSUs vest ratably on March 31, 2027, 2028, and 2029; accelerate fully on change in control.
- ·Performance bonuses paid in March 2027 post-audit, subject to continued service through Dec 31, 2026.
- ·Safety goals based on 2022-2025 national averages for Sunrise Coal and Hallador Power.
- ·Severance equals 12 months base salary (effective April 1, 2026) plus prior year bonus.
- ·Change-in-control retention requires 3-month post-closing work agreement with acquirer.
15-04-2026
On April 14, 2026, Mike Krieger resigned from the Board of Directors of Figma, Inc. effective immediately, with no disagreements on operations, policies, or practices. The Board expressed thanks for his service and contributions. No other changes or impacts were disclosed.
- ·Filing submitted on April 15, 2026, reporting event of April 14, 2026.
- ·Figma, Inc. is an emerging growth company.
15-04-2026
Structure Therapeutics Inc. (NASDAQ: GPCR) appointed Matthew Lang, J.D. as Chief Operating Officer and General Counsel, leveraging his over 15 years of executive experience from Metsera, Lyell Immunopharma, Myovant Sciences, and Gilead Sciences. CEO Raymond Stevens emphasized Lang's expertise in growth, strategic transactions, and commercialization, critical for advancing aleniglipron into Phase 3 trials. The appointment strengthens the leadership team amid a competitive obesity pipeline development.
- ·Announcement date: April 14, 2026
- ·Mr. Lang managed Myovant’s European operations in Basel, Switzerland
- ·Company pipeline targets GPCR for obesity and metabolic diseases via structure-based drug discovery platform
15-04-2026
World Acceptance Corporation (NASDAQ: WRLD) appointed Janet Matricciani as interim President and CEO effective April 13, 2026, following the resignation of R. Chad Prashad as President, CEO, and board member to pursue other opportunities. The board, chaired by Ken Bramlett, Jr., praised Ms. Matricciani's prior CEO experience and initiated a search for a permanent replacement. No immediate financial impacts were disclosed.
- ·Founded in 1962 and headquartered in Greenville, South Carolina.
- ·Fiscal year ended March 31, 2025 (reference to latest 10-K).
- ·Website: www.loansbyworld.com.
15-04-2026
Luther C. Kissam, IV, a member of OGE Energy Corp.'s Board of Directors, informed the company on April 13, 2026, that he will not stand for re-election and will resign effective at the annual shareholder meeting on May 14, 2026, due to accepting a new CEO position at another company. There are no disagreements with the company's operations, policies, or practices. The Board size will reduce to eight directors, and proxy materials have been amended to remove him as a nominee.
- ·Mr. Kissam has served more than five years on the Board and various committees.
- ·Previously voted proxies remain valid except with respect to Mr. Kissam.
- ·Annual shareholder meeting scheduled for May 14, 2026.
15-04-2026
Regis Corporation (Nasdaq: RGS) announced the appointment of William 'Bill' Charters as an independent director, effective April 24, 2026, adding expertise in capital markets, restructurings, and franchise models from one of its largest individual shareholders. Susan Lintonsmith, President and CEO, highlighted his value in executing the transformation strategy and enhancing shareholder value. The Board now consists of seven directors, six independent.
- ·Mr. Charters is a CFA charterholder with experience at Botti Brown Asset Management (multi-billion-dollar hedge fund).
- ·Investor contacts: James Carbonara (646-755-7412) and Brett Maas (646-536-7331) at Hayden IR.
15-04-2026
Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the appointment of Dr. Charles Morris, M.D. as Chief Medical Officer effective April 20, 2026, to lead the advancement of its two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer into clinical development in 2026. Dr. Morris brings over 30 years of oncology drug development experience, including prior CMO roles at Lava Therapeutics, Celyad Oncology, Radius Health, ImmunoGen, and Allos Therapeutics, and contributions to approvals of ONSERDU, ELAHERE, and Faslodex. CEO Kris Vaddi highlighted Dr. Morris's expertise as instrumental for executing these programs with rigor.
- ·Dr. Morris holds a medical degree and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from Sheffield University Medical School and is a Member of the Royal College of Physicians of London.
- ·Investor contact: Robert A. Doody, Jr. at 484.639.7235 or rdoody@preludetx.com
15-04-2026
Mount Logan Capital Inc. appointed Jordan Mangum, age 33, as Executive Vice President and Chief Operating Officer effective April 13, 2026, following a board decision on April 9, 2026. Mr. Mangum will continue his role as a Director on the credit team at BC Partners Advisors L.P. (BCPA), with services provided under the Staffing and Resource Agreement (dated November 18, 2025) and Servicing Agreement (dated March 17, 2023). Potential conflicts of interest exist due to the Company's reliance on BCPA for asset management and BCPA's minority equity interest via an affiliate.
- ·Mr. Mangum joined BCPA in March 2022, worked at Onex Private Credit division from March 2020 to March 2022, and held roles at Bank of America Merrill Lynch Global Corporate and Investment Banking from February 2015 to March 2020.
- ·Mr. Mangum holds a B.S. in Finance and a B.S. in Accounting from the Pamplin College of Business at Virginia Tech.
- ·No family relationships with current directors or officers; no new compensatory arrangements with the Company.
15-04-2026
On April 13, 2026, Trans-Lux Corporation accepted the resignation of John Hammock as Interim Chief Executive Officer, with no disagreements on operations, policies, or practices. The Board appointed Yantao (Tony) Yu, age 50 and previously a director since July 30, 2019, and COO since August 1, 2021, as the new CEO. Mr. Yu will receive $26,000 per year from the Company while also compensated by Unilumin, its largest stockholder.
- ·Mr. Yu has served as CFO of Unilumin USA since September 2018.
- ·Mr. Yu holds an Executive MBA from the University of Minnesota and certifications including CPA, CGA, CMA, and FCCA.
- ·Mr. Yu is not a party to any Item 404(a) transactions except his employment with the Company; no arrangements with others for his selection.
- ·Filing signed by Todd Dupee on April 15, 2026.
15-04-2026
On April 10, 2026, Michael Niggli notified ESS Tech, Inc. that he is resigning from the Board of Directors, Audit Committee, and Nominating and Corporate Governance Committee, effective as of the 2026 annual meeting of stockholders on May 29, 2026. The resignation was not the result of any disagreement with the Company on matters relating to its operations, policies, or practices. The Company expressed gratitude for Mr. Niggli's leadership as Founding Chairman and his years of service.
- ·Resignation notified on April 10, 2026
- ·Annual meeting scheduled for May 29, 2026
15-04-2026
On April 13, 2026, the Compensation Committee of Lionsgate Studios Corp. approved amendments to CEO Jon Feltheimer's employment agreement, extending the term to July 31, 2031, and granting him options to purchase 4,500,000 common shares at $11.07 per share and 666,667 RSUs in three performance-based tranches tied to stock price goals of $17.50, $20.00, and $22.50 over 20 consecutive trading days within five years. The amended agreement maintains his $1.5M annual base salary, $7.5M target bonus (up to 200% maximum), and provides for $10M target annual equity grants for fiscal years 2026 through 2029. No declines or flat performance metrics reported in this compensation-focused filing.
- ·Awards vest only if stock price goals achieved within 5 years and service through 5th anniversary (or qualifying termination)
- ·In change of control, achieved tranches subject only to time-vesting; others terminate
- ·Annual grants include time-vesting RSUs, options/SARs, and performance RSUs, vesting in 3 equal annual installments
- ·Performance-based annual RSUs contingent on 12-month metrics; all grants settle in shares, cash, or mix
- ·Severance upon without cause/good reason: PV of base salary to term end, target bonus, benefits continuation; full equity acceleration
- ·Retirement after 6 months notice: continued vesting of certain equity, 5-year exercise period
15-04-2026
Saga Communications, Inc. announced that CEO Christopher S. Forgy has resumed all regular duties and responsibilities following a temporary medical leave of absence that began on February 13, 2026, due to recovery from open heart surgery. During his intermittent absence, Mr. Forgy remained available for consultation on significant matters, returned part-time initially, and led the company's 4th Quarter and Year-End 2025 conference call on March 12, 2026. The executive team, led by COO Wayne Leland and CFO Samuel D. Bush, ensured continuity of operations.
- ·Medical leave required an indefinite period of recovery from open heart surgery.
- ·Filing signed by Samuel D. Bush on April 15, 2026.
15-04-2026
On April 10, 2026, the Board of Directors of Viskase Holdings, Inc. appointed Michael Blecic as Chief Financial Officer, effective immediately, while he continues as Vice President, Chief Accounting Officer, and Treasurer of subsidiary Viskase Companies, LLC, with no additional compensation beyond standard merit eligibility. The service of interim CFO Mackenzie Stender, provided through Silverman Consulting, Inc., was terminated on the same date. Additionally, Joseph D. King was appointed Executive Vice President, retaining his roles as Senior Vice President, General Counsel, and Secretary, also without extra compensation.
- ·Michael Blecic, age 57, joined Viskase Companies in 1995 and has held various positions since.
- ·No arrangements or understandings with other persons for Blecic's selection; no family relationships with directors/officers; no material interests under Item 404(a) of Regulation S-K.
15-04-2026
At EQT Corporation's Annual Meeting of Shareholders on April 14, 2026, all ten director nominees were elected with strong support, ranging from approximately 88% to 97% of votes cast (For votes between 450,207,215 and 498,018,181 shares). Shareholders also approved the Third Amendment to the 2020 Long-Term Incentive Plan, increasing authorized shares by 34,000,000, a non-binding say-on-pay resolution for 2025 (485,915,092 For), and ratification of Ernst & Young LLP as independent auditors for 2026 (513,890,206 For). All four proposals passed overwhelmingly, with broker non-votes at 37,393,505 shares for most items.
- ·Hallie A. Vanderhider received the lowest director support with 450,207,215 For, 63,277,105 Against, and 1,056,874 Abstained.
- ·Proposal 2 (Say-on-Pay) had 485,915,092 For, 27,460,142 Against, 1,165,960 Abstained.
- ·Proposal 4 (Auditor Ratification) had 513,890,206 For, 37,546,179 Against, 498,314 Abstained.
15-04-2026
Luke Kissam resigned from the Board of Directors of DuPont de Nemours, Inc. effective April 14, 2026, to assume the role of Chief Executive Officer at Corteva, Inc. The departure was not due to any disagreement with the Company's operations, policies, or practices. In response, the Board approved a reduction in its size from 11 to 10 members.
- ·Resignation tendered on April 13, 2026
- ·Date of Report (earliest event): April 13, 2026
- ·Filing date: April 15, 2026
15-04-2026
NextDecade Corporation entered into an amended and restated employment agreement with Matthew Schatzman, its Chairman and Chief Executive Officer, effective April 15, 2026, superseding his prior 2017 agreement. The agreement provides for an annual base salary of $1,000,000, a target annual bonus of 130% of base salary, eligibility for long-term incentives, and standard benefits. Severance includes 24 months of base salary plus 200% of target bonus upon termination without cause or for good reason, enhanced to 36 months base plus 300% target bonus if within 24 months post-change of control, with accelerated equity vesting.
- ·Initial term through April 15, 2029, with automatic one-year renewals unless 90 days' notice of non-renewal.
- ·Severance contingent on execution of release of claims.
- ·Includes customary non-competition, non-solicitation covenants, and confidentiality obligations.
15-04-2026
American Vanguard Corporation disclosed that directors Scott Baskin, Emer Gunter, and Carmen Tiu de Mino notified the Board on April 10, 2026, of their intention not to stand for re-election at the 2026 annual meeting, facilitating a reduction in Board size from nine to seven members as required by the First Lien Term Loan agreement entered March 13, 2026. These departures were not due to any disputes or disagreements with the Company. The Company plans to appoint one independent director in consultation with lenders led by Centerbridge Partners.
- ·Prior 8-K filed March 19, 2026, disclosed the Credit and Guaranty Agreement.
- ·Board changes required within 90 days following March 13, 2026.
15-04-2026
On April 10, 2026, Thomas R. Staab, II, Chief Financial Officer of LENSAR, Inc., notified the company of his intention to resign effective May 8, 2026, to pursue other professional opportunities. The resignation is not due to any disagreement with the company's operations, policies, or practices. LENSAR has commenced a search for a new CFO, with Mr. Staab continuing as principal financial officer through the transition date.
- ·The 8-K was filed on April 15, 2026.
15-04-2026
On April 10, 2026, 374Water Inc. (SCWO) appointed Richard H. Davis, an experienced investment banker and former director (2008-2025) and CEO of predecessor PowerVerde Inc., to its Board of Directors effective immediately. Mr. Davis will continue coordinating potential financing opportunities, with any successful transactions expected to exceed $120,000 in aggregate. He will receive standard non-employee director compensation, with no board committee assignments determined yet and no other material arrangements disclosed.
- ·Mr. Davis, age 69, holds a B.S. in economics from Florida State University (1982).
- ·Mr. Davis previously served as Board director from February 2008 to June 10, 2025.
- ·No transactions requiring disclosure under Item 404(a) of Regulation S-K involving Mr. Davis or his immediate family.
15-04-2026
Michael R. Heaton resigned from Hagerty, Inc.'s Board of Directors on April 13, 2026, as the designee of Markel Group Inc. under the Investor Rights Agreement, with no disagreements on company matters. The Board accelerated vesting of 10,230 RSUs granted to Heaton on July 1, 2025, originally scheduled for July 1, 2026. Markel designated Henrik W. Bjørnstad as the new Board member, appointed effective April 14, 2026, to the Talent, Culture, and Compensation Committee and the Nominating and Governance Committee.
- ·Investor Rights Agreement dated August 17, 2021
- ·Mr. Bjørnstad entitled to standard non-employee director compensation per proxy statement filed April 24, 2025
- ·No transactions requiring disclosure under Item 404(a) of Regulation S-K involving Mr. Bjørnstad
15-04-2026
Corebridge Financial, Inc. appointed Christopher Filiaggi, its Chief Accounting Officer since June 2023, as Interim Chief Financial Officer effective April 24, 2026, succeeding Elias Habayeb who will depart on the same date, in preparation for the company's planned merger with Equitable Holdings, Inc. Filiaggi will serve until merger close, when Equitable Holdings' CFO Robin M. Raju will assume the role for the combined entity. The company manages $385 billion in assets under management and administration as of December 31, 2025, amid forward-looking statements cautioning on merger risks including regulatory approvals and integration challenges.
- ·Filiaggi previously held finance leadership positions at Corebridge and AIG, and advised insurance clients at PricewaterhouseCoopers LLP on accounting and compliance.
- ·Merger forward-looking risks include regulatory approvals, integration delays, business disruptions, and potential failure to realize synergies.
15-04-2026
Valmont Industries Inc disclosed the compensation package for John Schwietz via Exhibit 99.1 in its 8-K filing. Key elements include a base salary of $525,000 per year, participation in the 2026 Annual Incentive Plan (AIP) with a target of 80% of base salary (prorated for 2026 and capped at 2x target), and Long Term Performance Share (LTIP) plans for 2025-2027 and 2026-2028 with a target of 80% of base salary (prorated from promotion date and capped at 2x target). Additional components are eligibility for a December 2026 stock grant with a target value of 160% of base salary and a stock ownership guideline of 2.5x base salary.
- ·AIP and LTIP prorated from promotion date
- ·Stock grant eligibility in December 2026
15-04-2026
Cineverse Corp. (Nasdaq: CNVS) announced the appointment of Sean McCabe as CFO effective April 20, 2026, marking his return after serving as VP and corporate controller in 2023-2024 and a leadership role at Freestar. McCabe succeeds Mark Lindsey, who served 3.5 years and is in discussions for a senior financial consulting role. CEO Chris McGurk highlighted McCabe's ad-tech experience to support recent acquisitions like IndiCue and Giant Worldwide, aiming to strengthen the balance sheet and pursue strategic opportunities.
- ·McCabe's prior roles include controller positions at Jukin Media, Fulgent Genetics, and National Grid, starting career at PricewaterhouseCoopers in auditing and M&A.
- ·Recent strategic acquisitions: Giant Worldwide and IndiCue, now Matchpoint companies, with IndiCue adding significant revenues and profits.
15-04-2026
On April 10, 2026, Neal Dongre notified MSC Industrial Direct Co., Inc. of his voluntary resignation as Senior Vice President, General Counsel, and Corporate Secretary, with no disagreements regarding the company's operations, policies, or practices. Mr. Dongre will remain in his position until a successor joins the company and will continue as an employee through the remainder of fiscal year 2026. The filing was signed by Greg Clark, Vice President and Interim Chief Financial Officer.
- ·Filing date: April 15, 2026
- ·Company address: 515 Broadhollow Road, Suite 1000, Melville, New York 11747
- ·Class A Common Stock traded on New York Stock Exchange under symbol MSM
15-04-2026
Starz Entertainment Corp. announced on April 9, 2026, that Audrey Lee, Executive Vice President and General Counsel, will retire effective May 1, 2026, and remain available for consultation through May 31, 2026. Under the Separation Letter dated April 15, 2026, she will receive a lump-sum cash payment of $1,226,077.36 (18 months of base salary), an additional lump-sum of $858,254.15 (70% of the base salary amount), COBRA premium payments for up to 18 months, and accelerated vesting of outstanding equity awards. The agreement confirms she is ineligible for the 2026 equity grant cycle and satisfies her prior severance agreement.
- ·Separation satisfies conditions under Section 1(a) of Starz Severance Agreement dated June 1, 2022
- ·Separation Letter filed as Exhibit 10.1
15-04-2026
Ribbon Communications Inc. (Nasdaq: RBBN) appointed Louis Silver to its Board of Directors effective April 15, 2026, increasing the board size to nine members, six of whom are independent. Silver, a corporate advisor and Managing Director for Alba Capital S.A. and Wicklow Corp., brings over 25 years of experience in technology investments, finance, governance, and compliance, and currently serves on the board of Ceva, Inc. The appointment is as a designee of Swarth Investments Ltd. pursuant to the Company’s Stockholders Agreement.
- ·Mr. Silver previously served as Principal at RP Capital UK Ltd. from 2005 to 2015.
- ·Mr. Silver is Chairman of the Audit Committee and member of the Compensation Committee at Ceva, Inc.
- ·Investor Contact: +1 (978) 614-8050, ir@rbbn.com
15-04-2026
Kenvue Inc. announced that CFO Amit Banati will step down effective May 12, 2026, with Heather Howlett, the current Chief Accounting Officer, appointed as interim CFO and Chief Accounting Officer starting the same date until the merger closing with Kimberly-Clark Corporation. Ms. Howlett, age 48, will receive a $125,000 monthly stipend in addition to her unchanged FY2026 compensation of $544,116 base salary, $299,264 target bonus, and $420,000 equity award. No other changes to her benefits or severance eligibility.
- ·Amit Banati departure announced February 12, 2026.
- ·Heather Howlett joined Johnson & Johnson in September 2022 and Kenvue as CAO in May 2023; prior roles at Trane Technologies (March 2020-August 2022).
- ·No family relationships or arrangements influencing Howlett's appointment.
- ·Stipend not counted toward annual bonus, severance, or 401(k).
- ·Appointment effective April 10, 2026 filing; Heather Howlett serves as principal financial and accounting officer during interim term.
15-04-2026
USBC, Inc. reported the departure of Ronald P. Erickson as a member of the Board of Directors and President of the Science Division effective March 27, 2026, following the divestiture of its legacy non-invasive sensor technology business, with no disagreements on operations, policies, or practices. In connection with his separation, the Company entered into a Separation Agreement on April 9, 2026, providing severance payments equal to his $375,000 annual base salary over one year and full acceleration of 167,500 unvested restricted shares. Certain post-termination obligations from his August 6, 2025 employment agreement remain in effect.
- ·Separation Agreement executed April 9, 2026; to be filed as exhibit to 10-Q for quarter ended March 31, 2026
- ·Divestiture closed March 27, 2026 pursuant to Stock Purchase Agreement
- ·Equity award from Private Placement closing August 6, 2025
- ·Employment agreement dated August 6, 2025
15-04-2026
Tango Therapeutics, Inc. (NASDAQ: TNGX) announced leadership appointments to accelerate late-stage development of vopimetostat, including Matthew Gall as Chief Financial Officer effective April 15, 2026, succeeding Daniella Beckman; Yen-Ching Chua as Chief Development Operations Officer effective June 1, 2026; and Janice Kapty, PhD as SVP, Corporate Strategy and Project Leadership effective April 15, 2026. These hires bring expertise from prior roles at companies like iTeos Therapeutics, Novartis, and Arvinas to support vopimetostat's potential regulatory approval in pancreatic cancer and upcoming clinical data presentations in 2026. The departure of prior CFO Daniella Beckman was acknowledged with gratitude for her contributions, including the company's IPO and capital raises.
- ·Company plans to present key clinical data in 2026, including initial data from combination trial with Revolution Medicines’ RAS(ON) inhibitors
- ·Prior CFO Daniella Beckman contributed to taking the company public and leading multiple capital raises
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 29 filings
🇺🇸 More from United States
View all →April 08, 2026
US Pre-Market SEC Filings Roundup — April 08, 2026
US Pre-Market SEC Filings Roundup
April 08, 2026
US Merger & Acquisition SEC Filings — April 08, 2026
US Merger & Acquisition SEC Filings
April 08, 2026
US Corporate Board Director Changes SEC Filings — April 08, 2026
US Corporate Board Director Changes SEC Filings
April 08, 2026
US Corporate Distress Financial Stress SEC Filings — April 08, 2026
US Corporate Distress Financial Stress SEC Filings